C07K 7/50
Cyclic peptides containing at least one abnormal peptide link
C07K7/50 (Cyclic peptides containing at least one abnormal peptide link) appears on 825 US grants and 1,039 published applications in this corpus.
Search patents in C07K- Granted patents
- 825
- Published applications
- 1,039
- Assignees
- 512
- Inventors
- 2,583
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 3 | 0 |
| 1978 | 2 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 17 | 0 |
| 1982 | 6 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 3 | 0 |
| 1989 | 1 | 0 |
| 1990 | 3 | 0 |
| 1991 | 5 | 0 |
| 1992 | 10 | 0 |
| 1993 | 7 | 0 |
| 1994 | 11 | 0 |
| 1995 | 14 | 0 |
| 1996 | 14 | 0 |
| 1997 | 28 | 0 |
| 1998 | 18 | 0 |
| 1999 | 21 | 0 |
| 2000 | 17 | 0 |
| 2001 | 17 | 0 |
| 2002 | 14 | 16 |
| 2003 | 21 | 15 |
| 2004 | 16 | 21 |
| 2005 | 10 | 27 |
| 2006 | 14 | 21 |
| 2007 | 16 | 20 |
| 2008 | 9 | 24 |
| 2009 | 10 | 28 |
| 2010 | 13 | 33 |
| 2011 | 18 | 21 |
| 2012 | 9 | 34 |
| 2013 | 23 | 57 |
| 2014 | 36 | 53 |
| 2015 | 50 | 45 |
| 2016 | 36 | 57 |
| 2017 | 34 | 55 |
| 2018 | 40 | 50 |
| 2019 | 36 | 63 |
| 2020 | 39 | 55 |
| 2021 | 43 | 63 |
| 2022 | 35 | 58 |
| 2023 | 23 | 53 |
| 2024 | 32 | 65 |
| 2025 | 26 | 65 |
| 2026 | 19 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cyclic peptide and preparation method and use thereof15 Sep 2026US 12,735,456 B2Hangzhou Huibo Science and Technology Co., Ltd
- Multicyclic peptides and methods for their preparation1 Sep 2026US 12,723,059 B2Universiteit Van Amsterdam
- Preparation method, intermediates, and use of cyclic peptide toxin alpha-amanitin and/or amaninamide1 Sep 2026US 12,723,060 B2Inner Mongolia Duhe Innovation R & D Tech Co., Ltd
- Diamine-linked melanocortin receptor-specific cyclic peptides for ocular indications28 Jul 2026US 12,692,291 B2Boehringer Ingelheim International GmbH
- Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases7 Jul 2026US 12,673,974 B2Protagonist Therapeutics, Inc.
- Cyclic compounds for treating cancer8 Oct 2026US 2026/0308204 A1University of South Florida
- Melanocortin receptor ligands modified with hydantoin1 Oct 2026US 2026/0297130 A1Ipsen Pharma S.A.S.
- Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras1 Oct 2026US 2026/0297133 A1Chugai Seiyaku Kabushiki Kaisha
- Universal abt compounds and uses thereof24 Sep 2026US 2026/0284204 A1Kleo Pharmaceuticals, Inc.
- Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases24 Sep 2026US 2026/0285908 A1Protagonist Therapeutics, Inc.
Most cited
By later US patents
- Modular pressure support system184US 7,677,246 B2RIC Investments, LLC · 2010
- Cyclic cell adhesion modulation compounds101US 5,192,746 ATanabe Seiyaku Co., Ltd. · 1993
- Methods for preparing internally constrained peptides and peptidomimetics82US 7,202,332 B2New York University · 2007
- Method to identify analyte-bending ligands78US 5,133,866 ATerrapin Technologies, Inc. · 1992
- Conformationally constrained backbone cyclized peptide analogs73US 5,874,529 APeptor Limited · 1999